NUK - logo
E-viri
Recenzirano Odprti dostop
  • In vitro susceptibility of ...
    Li, Henry; Estabrook, Mark; Jacoby, George A; Nichols, Wright W; Testa, Raymond T; Bush, Karen

    Antimicrobial agents and chemotherapy, 03/2015, Letnik: 59, Številka: 3
    Journal Article

    Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline, or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases from all molecular classes. Most strains were nonsusceptible to the β-lactams alone. Against AmpC-, extended-spectrum β-lactamase (ESBL)-, and KPC-producing Enterobacteriaceae or Pseudomonas aeruginosa, avibactam lowered ceftazidime, ceftaroline, or aztreonam MICs up to 2,048-fold, to ≤4 μg/ml. Aztreonam-avibactam MICs against a VIM-1 metallo-β-lactamase-producing Enterobacter cloacae and a VIM-1/KPC-3-producing Escherichia coli isolate were 0.12 and 8 μg/ml, respectively.